EA201000787A1 - Антигенсвязывающие белки - Google Patents

Антигенсвязывающие белки

Info

Publication number
EA201000787A1
EA201000787A1 EA201000787A EA201000787A EA201000787A1 EA 201000787 A1 EA201000787 A1 EA 201000787A1 EA 201000787 A EA201000787 A EA 201000787A EA 201000787 A EA201000787 A EA 201000787A EA 201000787 A1 EA201000787 A1 EA 201000787A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
binding proteins
diseases
elevated levels
proteins
Prior art date
Application number
EA201000787A
Other languages
English (en)
Other versions
EA022913B1 (ru
Inventor
Филипп Марк Луи Алар
Джонатан Генри Эллис
Сюзанна Карен Форд
Фолькер Гермашевски
Алан Питер Льюис
Питер Эрнест Соден
Памела Джоан Томас
Тревор Энтони Кеннет Уоттам
Джеральд Уэйн Гоф
Айан Ричард Кэтчпол
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201000787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0724185A external-priority patent/GB0724185D0/en
Priority claimed from GB0806230A external-priority patent/GB0806230D0/en
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201000787A1 publication Critical patent/EA201000787A1/ru
Publication of EA022913B1 publication Critical patent/EA022913B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Антигенсвязывающие белки, которые связываются с β-амилоидным пептидом, в частности β-амилоидным пептидом человека; способы лечения заболеваний или расстройств, характеризующихся повышенными уровнями β-амилоида или β-амилоидными отложениями, в частности болезни Альцгеймера, и заболеваний или расстройств, поражающих глаз или зрительный нерв, характеризующихся повышенными уровнями β-амилоида или β-амилоидными отложениями, включая возрастную макулярную дегенерацию, и заболевания глаукомой разного типа, и образование β-амилоидзависимой катаракты указанными антигенсвязывающими белками; фармацевтические композиции, содержащие указанные антигенсвязывающие белки; и способы изготовления.
EA201000787A 2007-12-11 2008-12-09 Антигенсвязывающие белки EA022913B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0724185A GB0724185D0 (en) 2007-12-11 2007-12-11 Antibodies
GB0806230A GB0806230D0 (en) 2008-04-04 2008-04-04 Antibodies
US4383908P 2008-04-10 2008-04-10
PCT/EP2008/067138 WO2009074583A1 (en) 2007-12-11 2008-12-09 Antigen binding proteins

Publications (2)

Publication Number Publication Date
EA201000787A1 true EA201000787A1 (ru) 2010-12-30
EA022913B1 EA022913B1 (ru) 2016-03-31

Family

ID=40547800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000787A EA022913B1 (ru) 2007-12-11 2008-12-09 Антигенсвязывающие белки

Country Status (24)

Country Link
US (2) US20110014182A1 (ru)
EP (1) EP2222705B1 (ru)
JP (2) JP5512537B2 (ru)
KR (2) KR101657637B1 (ru)
CN (1) CN101970484B (ru)
AR (1) AR069610A1 (ru)
AU (1) AU2008334637B2 (ru)
BR (1) BRPI0819916A2 (ru)
CA (1) CA2707859A1 (ru)
CL (1) CL2008003655A1 (ru)
CO (1) CO6280540A2 (ru)
CR (1) CR11561A (ru)
DO (1) DOP2010000170A (ru)
EA (1) EA022913B1 (ru)
ES (1) ES2525704T3 (ru)
IL (1) IL206188A0 (ru)
MA (1) MA31999B1 (ru)
MX (1) MX2010006422A (ru)
NZ (1) NZ586003A (ru)
PE (1) PE20091449A1 (ru)
TW (1) TWI388334B (ru)
UY (1) UY31520A1 (ru)
WO (1) WO2009074583A1 (ru)
ZA (1) ZA201004133B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2238166T1 (sl) 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CA2832106A1 (en) * 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US9512212B2 (en) * 2012-01-11 2016-12-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
EP3060581A4 (en) * 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CA2939191C (en) * 2014-02-10 2023-04-04 Igm Biosciences, Inc. Iga multi-specific binding molecules
KR102626877B1 (ko) * 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
ES2888904T3 (es) * 2016-10-19 2022-01-10 Alexion Pharma Inc Un método de cuantificación de C5a sin unir en una muestra
US11965884B2 (en) * 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
US20230126447A1 (en) * 2020-03-10 2023-04-27 Achillion Pharmaceuticals, Inc. Ocular drug depot for complement-mediated disorders
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) * 2020-07-13 2023-10-20 中国科学技术大学 检测bace1酶活性的试剂盒及用途
CN117131608B (zh) * 2023-10-23 2024-03-15 南京航空航天大学 一种基于最佳环量分布的激励盘方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308461A3 (en) * 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ES2277683T3 (es) * 1999-07-23 2007-07-16 Glaxo Group Limited Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico.
WO2003076455A2 (en) 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
EP1596809B1 (en) 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Abeta binding molecules
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
ES2338179T3 (es) * 2006-03-30 2010-05-04 Glaxo Group Limited Anticuerpos contra el peptido beta-amiloide.
US20090022728A1 (en) 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases

Also Published As

Publication number Publication date
KR101657637B1 (ko) 2016-09-19
ES2525704T3 (es) 2014-12-29
CN101970484B (zh) 2014-10-01
EA022913B1 (ru) 2016-03-31
US20110014182A1 (en) 2011-01-20
NZ586003A (en) 2012-08-31
WO2009074583A1 (en) 2009-06-18
TW200932267A (en) 2009-08-01
PE20091449A1 (es) 2009-10-07
ZA201004133B (en) 2011-11-30
CO6280540A2 (es) 2011-05-20
US8921523B2 (en) 2014-12-30
KR20100099277A (ko) 2010-09-10
BRPI0819916A2 (pt) 2015-05-19
AU2008334637B2 (en) 2014-08-07
UY31520A1 (es) 2009-08-03
EP2222705A1 (en) 2010-09-01
EP2222705B1 (en) 2014-10-22
JP5512537B2 (ja) 2014-06-04
JP2011506387A (ja) 2011-03-03
MA31999B1 (fr) 2011-01-03
KR101629365B1 (ko) 2016-06-14
KR20150100964A (ko) 2015-09-02
AR069610A1 (es) 2010-02-03
AU2008334637A1 (en) 2009-06-18
US20090162358A1 (en) 2009-06-25
MX2010006422A (es) 2010-06-25
TWI388334B (zh) 2013-03-11
CN101970484A (zh) 2011-02-09
JP2014177462A (ja) 2014-09-25
DOP2010000170A (es) 2010-08-15
CA2707859A1 (en) 2009-06-18
CL2008003655A1 (es) 2010-04-16
CR11561A (es) 2010-09-23
IL206188A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
EA201000787A1 (ru) Антигенсвязывающие белки
EA200701828A1 (ru) Композиции для лечения ретинол-ассоциированных заболеваний
WO2006091796A3 (en) Compositions and methods for diagnosing and treating retinal diseases
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
PH12011502389B1 (en) Monoclonal antibody
SI2206728T1 (en) Methods for the treatment of bone cancer pain by administration of an antagonist nerve growth factor
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
MX2010003667A (es) Compuestos alcoxi para el tratamiento de enfermedades.
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
RS53174B (en) USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
RU2015121755A (ru) Антагонисты ил-6 и их применение
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
RU2009133789A (ru) Способы лечения глазных болезней
UA116614C2 (uk) Антитіло до фактора d і його застосування
DE602006019948D1 (de) Koppelten rezeptors zur behandlung von makuladegeneration
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU